Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05980806 · ClinicalTrials.gov registry record · Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
A Phase 2 study of Myelofibrosis and Moderate Thrombocytopenia, sponsored by Karyopharm Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 20
- Study locations
NCT05980806 is a Phase 2 study of Myelofibrosis and Moderate Thrombocytopenia that is actively recruiting participants, run by Karyopharm Therapeutics. The registered enrollment target is 58 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05980806, a Phase 2 study of Myelofibrosis and Moderate Thrombocytopenia, is actively recruiting participants, sponsored by Karyopharm Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Momelotinib
- DRUG Pacritinib
- DRUG Selinexor 60 mg
- DRUG Selinexor 40 mg
Study Locations (20)
Other
- UZ Gent - Ghent
- UZ Leuven - Campus Gasthuisberg - Leuven
- University Multiprofile Hospital for Active Treatment Sveti George - Base 1 - Plovdiv
- University Hospital Sv.Ivan Rilski - Sofia - Sofia
- University Multiprofile Hospital for Active Treatment Aleksandrovska - Sofia
- Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia - Sofia
- University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD Department of Clinical Hematology - Stara Zagora
- Fakultní nemocnice Olomouc - Olomouc
California
- City of Hope - Duarte Main Site - Duarte
Maryland
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology - Columbia
New York
- Weill Cornell Medicine NewYork-Presbyterian - New York
North Carolina
- Duke University - Durham
Ohio
- Cleveland Clinic - Cleveland
Texas
- MD Anderson - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05980806
The ClinicalTrials.gov registry entry for NCT05980806 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (70% lower). The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 5 interventions - of which Ruxolitinib is the first listed.
NCT05980806 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05980806 about?
NCT05980806 is a clinical study titled "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia". The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed...
What is the current status of trial NCT05980806?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2024-04-22. Estimated completion is 2028-10.
What conditions does trial NCT05980806 study?
This clinical trial studies the following conditions: Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia.
What interventions are being tested in trial NCT05980806?
The interventions under investigation include: Ruxolitinib (DRUG), Momelotinib (DRUG), Pacritinib (DRUG), Selinexor 60 mg (DRUG), Selinexor 40 mg (DRUG).
Who is sponsoring clinical trial NCT05980806?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05980806 being conducted?
This trial has 20 study locations across California, Maryland, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.